GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

GRAIL Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GRAIL Inc (GRAL – Research Report) and Bicycle Thera...

Analysts’ Top Healthcare Picks: GRAIL Inc (GRAL), Bicycle Therapeutics (BCYC)

In a report released yesterday, Subbu Nambi from Guggenheim maintained a Buy rating on GRAIL Inc, with a price target of $130.00. The company’s sha...

Guggenheim Sticks to Their Buy Rating for GRAIL Inc (GRAL)

In a report released today, Kyle Mikson CFA from Canaccord Genuity reiterated a Buy rating on GRAIL Inc, with a price target of $80.00. Mikson CFA ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GRAL	$54.99	0.00%	792.40K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GRAL	$54.99	0%	792.40K
3
4
5
6

GRAL

GRAL

Dividend Overview

Get GRAIL Inc. Data in Excel

Get GRAIL Inc. Data in Excel